Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

surgery

SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant

July 1, 2025 Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine

SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
News

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025 Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
News
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025 Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
News

Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development

June 30, 2025 Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics

Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …
Appointment

Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin

June 27, 2025 Research and Development Dermatology, Galderma, chronic pruritus of unknown origin, clinical trials, dermatological conditions, dermatology, nemolizumab, systemic sclerosis

Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic …
News

STENTiT treats first patient with regenerative stent for limb preservation

June 27, 2025 Research and Development Cardiology, Medical University of Graz, STENTiT, chronic limb-threatening ischemia, clinical trial, limb amputation, peripheral artery disease, regenerative stent, resorbable fibrillated scaffold

STENTiT has announced the successful first patient implantation of its resorbable fibrillated scaffold (RFS), a new regenerative stent, as part …
News

Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases

June 27, 2025 Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners

Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …
News

CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany

June 26, 2025 Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access

CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
News
Photo of patient

FDA grants orphan drug designation to antibody-mediated rejection treatment

June 26, 2025 Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation

Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
News
money_pills_2

Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses

June 26, 2025 Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation

Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …
News
blood_test

Roche candidate shows early promise for treating haemophilia A

June 25, 2025 Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
News
weight-2036971_960_720

Novo Nordisk’s therapy delivers significant weight loss in trial

June 25, 2025 Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions

Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
News

Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn

June 25, 2025 Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution

Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …
Appointment

PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board

June 25, 2025 Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board

PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …
Appointment

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025 Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026